Bremelanotide vs Kisspeptin
Bremelanotide has Phase III HSDD outcome evidence; kisspeptin has smaller mechanistic HSDD studies and reproductive-medicine research.
| Attribute | Bremelanotide | Kisspeptin |
|---|---|---|
| Human evidence | Two Phase III RECONNECT trials support bremelanotide for acquired generalized HSDD in premenopausal women. Older intranasal studies also reported male ED signals, but that is not the approved indication. | Controlled human studies demonstrate reproductive-hormone effects, oocyte-maturation triggering in specialist IVF settings, and acute sexual/emotional brain-processing effects in small randomized HSDD studies in men and women. Long-term HSDD efficacy is not established. |
| Research focus | Hypoactive sexual desire disorder (HSDD) | Reproductive endocrinology, fertility, psychosexual research |
| Regulatory status | U.S. Vyleesi is approved for acquired generalized HSDD in premenopausal women; it is not indicated for men or to enhance sexual performance. | No general FDA-approved kisspeptin therapy identified. |
| Route / formulation | Research-market PT-141 is not automatically equivalent to the authorised Vyleesi product. | Evidence differs between kisspeptin-10 and kisspeptin-54 and between IV and other routes. |
Why these are compared
These compounds appear in the sexual desire / arousal research evidence landscape, but they are not interchangeable. Bremelanotide is cyclic melanocortin receptor agonist peptide studied in hypoactive sexual desire disorder (hsdd); Kisspeptin is reproductive neuropeptide studied in reproductive endocrinology, fertility, psychosexual research. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
Bremelanotide: Approved medicine — strong evidence for narrow HSDD indication.
Kisspeptin: Human experimental/reproductive evidence; investigational outside specialist research.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
No head-to-head outcome trial. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty.